SmithKline & French agreement
Executive Summary
With Norwegian firm Nycomed covers the research and development of hemoregulatory peptides for use in cancer therapy. The compounds are intended to help patients endure larger doses of cytostatic agents and radiotherapy by accelerating recovery of bone marrow function.